Cargando…

Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan

OBJECTIVE: Gastroesophageal reflux disease (GERD) is a highly prevalent disorder that negatively affects patients' quality of life and reduces their work productivity. The medical expenses associated with the treatment of GERD are the highest among all digestive diseases. Current guidelines rec...

Descripción completa

Detalles Bibliográficos
Autor principal:	Habu, Yasuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761357/ https://www.ncbi.nlm.nih.gov/pubmed/31178490 http://dx.doi.org/10.2169/internalmedicine.2535-18

Ejemplares similares

Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China
por: Wang, Zhenhua, et al.
Publicado: (2022)

Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole
por: Ashida, Kiyoshi, et al.
Publicado: (2018)

Treatment strategies for reflux esophagitis including a potassium‐competitive acid blocker: A cost‐effectiveness analysis in Japan
por: Habu, Yasuki, et al.
Publicado: (2021)

Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease
por: Gotoh, Yasuhiko, et al.
Publicado: (2020)

Long-Term Efficacy of Lansoprazole in Preventing Relapse of Erosive Reflux Esophagitis
por: Kovacs, Thomas O., et al.
Publicado: (2009)

Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial
por: Kawai, Daisuke, et al.
Publicado: (2021)

Comparison of the early effects of vonoprazan, lansoprazole and famotidine on intragastric pH: a three-way crossover study
por: Ohkuma, Kanji, et al.
Publicado: (2018)

The Development of Foveolar-type Gastric Adenocarcinoma during Maintenance Therapy of Vonoprazan for Reflux Esophagitis
por: Saito, Masahiro, et al.
Publicado: (2020)

Vonoprazan 20 mg vs lansoprazole 30 mg for endoscopic submucosal dissection-induced gastric ulcers
por: Takahashi, Kazuya, et al.
Publicado: (2016)

Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication
por: Huh, Ki Young, et al.
Publicado: (2021)

Vonoprazan vs lansoprazole for the treatment of artificial gastric ulcer after endoscopic submucosal dissection: a prospective randomized comparative study
por: Ban, Hiromitsu, et al.
Publicado: (2021)

Lansoprazole plus levosulpiride versus esomeprazole in participants with gastroesophageal reflux disease and erosive esophagitis: a double blinded randomized control trial
por: Umer, Muhammad Rizwan, et al.
Publicado: (2023)

Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis
por: Ashida, K., et al.
Publicado: (2015)

The role of vonoprazan in patients with erosive esophagitis
por: Zhang, Mengyu, et al.
Publicado: (2022)

Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors
por: Mizuno, Hideki, et al.
Publicado: (2018)

Lansoprazole-Induced Improvement of Esophageal Submucosal Injury
por: Mine, Shinichiro, et al.
Publicado: (2007)

Randomised clinical trial: a dose‐ranging study of vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis
por: Ashida, K., et al.
Publicado: (2015)

Use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease
por: Tabuchi, Maiko, et al.
Publicado: (2021)

Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis
por: Xiao, Yinglian, et al.
Publicado: (2020)

Cost-Effectiveness of Vonoprazan- and Rifabutin-Based Regimens
por: Almenoff, June
Publicado: (2023)

Importance of Metronidazole in Vonoprazan-based Helicobacter pylori Treatment in Japan
por: Suzuki, Sho, et al.
Publicado: (2023)

Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study
por: Mizokami, Yuji, et al.
Publicado: (2018)

Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease
por: Niikura, Ryota, et al.
Publicado: (2018)

Vonoprazan versus proton pump inhibitors for the management of gastroesophageal reflux disease: A protocol for a systematic review with meta-analysis
por: Kang, Hyun, et al.
Publicado: (2018)

Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan
por: Sugimoto, Mitsushige, et al.
Publicado: (2019)

Efficacy, safety and cost-effectiveness of vonoprazan vs Proton Pump Inhibitors in reflux disorders and H. pylori eradication: A literature review
por: Shehryar, Muhammad, et al.
Publicado: (2022)

Long-Term Quality of Life Improvement in Subjects with Healed Erosive Esophagitis: Treatment with Lansoprazole
por: Kovacs, Thomas O., et al.
Publicado: (2009)

The adjuvant use of lansoprazole, clonazepam and dimenhydrinate for treating intractable hiccups in a patient with gastritis and reflux esophagitis complicated with myocardial infarction: a case report
por: Maximov, Georgi Konstantinov, et al.
Publicado: (2013)

Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan
por: Sakurai, Kouichi, et al.
Publicado: (2018)

Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers – results from two phase 3, non‐inferiority randomised controlled trials
por: Miwa, H., et al.
Publicado: (2016)

Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease
por: Miwa, Hiroto, et al.
Publicado: (2019)

Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis
por: Yang, Sensen, et al.
Publicado: (2022)

Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon?
por: Abadi, Amin Talebi Bezmin, et al.
Publicado: (2019)

Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats
por: Shen, Jiquan, et al.
Publicado: (2020)

A Multicenter, Randomized, Comparative Study to Determine the Appropriate Dose of Lansoprazole for Use in the Diagnostic Test for Gastroesophageal Reflux Disease
por: Lee, Si Hyung, et al.
Publicado: (2011)

Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study
por: Kinoshita, Yoshikazu, et al.
Publicado: (2019)

The effect of adding duloxetine to lansoprazole on symptom and quality of life improvement in patients with gastroesophageal reflux diseases: A randomized double-blind clinical trial
por: Mokhtare, Marjan, et al.
Publicado: (2021)

Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan
por: Howden, Colin W., et al.
Publicado: (2023)

Immune and Inflammatory Responses in GERD and Lansoprazole
por: Isomoto, Hajime, et al.
Publicado: (2007)

Toxic epidermal necrolysis induced by lansoprazole()
por: Fracaroli, Tainá Scalfoni, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_13pifj4l95t55v38lmfingf4pm